IDEXX Laboratories, Inc. Q3 2025 Earnings Recap

IDXX Q3 2025 November 5, 2025

IDEXX Laboratories reported robust Q3 2025 results with a 13% rise in revenue, bolstered by strong performance in their Companion Animal Group (CAG) business despite some headwinds from clinical visit declines.

Earnings Per Share Beat

$3.40 vs $3.14 est.

+8.3% surprise

Revenue Beat

1105239000 vs 1073219249 est.

+3.0% surprise

Market Reaction

1-Day -0.9%

5-Day -0.92%

30-Day -1.88%

Key Takeaways

Revenue increased to $1.080 billion, a 13% year-over-year jump, with organic growth at 12%.
CAG Diagnostics recurring revenues grew 10% organically, driven by a significant rise in premium instrument placements, including over 1,750 InVue Dx analyzers resulting in 71% growth in instrument revenues.
Updated full-year guidance reflects increased revenue expectations of $4.270-$4.300 billion and EPS outlook raised to $12.81-$13.01, indicating strong operational momentum despite macro challenges.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit IDXX on AllInvestView.